← FDA DRUG APPROVALS

FDA ANDA · ANDA209044

AZITHROMYCIN

Sponsor: SUNSHINE

APPLICATION
ANDA209044
TYPE
ANDA
ORIGINAL APPROVAL
2018-12-07
LATEST ACTION
2022-10-11
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

AZITHROMYCINPrescription
AZITHROMYCIN EQ 500MG BASE · TABLET · ORAL

Approval history

2022-10-11Manufacturing (CMC) · Supplement 12 · unknownAP
2020-04-01Manufacturing (CMC) · Supplement 7 · unknownAP
2020-01-21Manufacturing (CMC) · Supplement 4AP
2019-02-19Manufacturing (CMC) · Supplement 1 · unknownAP
2018-12-07UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →